Terminology for Benign Pleural Disease
The accepted medical term for benign (non-malignant) pleural disease is "non-malignant pleural effusion" (NMPE), though it is also commonly referred to as "benign pleural effusion." 1
Key Terminology and Context
The 2024 European Respiratory Society statement explicitly defines this terminology, noting that non-malignant pleural effusions (NMPEs) are also known as "benign" pleural effusions 1. However, the guidelines emphasize an important caveat: the term "benign" is somewhat misleading given the significant morbidity and mortality associated with these conditions.
Important Clinical Reality
Despite being labeled "benign," these effusions carry substantial mortality rates:
- Heart failure-related effusions: 50% 1-year mortality
- Renal failure-related effusions: 46% 1-year mortality
- Liver failure-related effusions: 25% 1-year mortality
This renders the term "benign" a misnomer in many cases 1.
Specific Diagnostic Category: Nonspecific Pleuritis (NSP)
When pleural biopsy shows only inflammation and fibrosis without definitive features of malignancy, tuberculosis, or other specific diseases, the histological diagnosis is termed "nonspecific pleuritis" (NSP) 1. This occurs in up to 40% of pleural biopsies and represents a diagnostic challenge, as 8-12% of NSP cases eventually prove to be malignancy, particularly mesothelioma 1, 2.
Common Causes of NMPE Include:
- Transudative effusions (heart failure, hepatic hydrothorax, end-stage renal failure)
- Benign asbestos-related pleural effusion
- Post-surgical effusion
- Nonspecific pleuritis
- Inflammatory conditions (rheumatoid arthritis, drug-induced)
Epidemiological Significance
NMPEs are far more common than malignant effusions, with an estimated incidence of 252 per 100,000 population compared to the overall pleural effusion incidence of 337 per 100,000 1. These conditions account for approximately 75% of total healthcare resource allocation for pleural effusion management in the United States 1.